RMTI - Rockwell Medical, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.4700
+0.3200 (+10.16%)
At close: 4:00PM EST

3.47 0.00 (0.00%)
After hours: 4:44PM EST

Stock chart is not supported by your current browser
Previous Close3.1500
Open3.1500
Bid3.00 x 1100
Ask3.55 x 1400
Day's Range3.1500 - 3.5400
52 Week Range2.1900 - 6.9200
Volume187,059
Avg. Volume228,875
Market Cap197.713M
Beta (3Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.62
Earnings DateMar 13, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • Rockwell Medical, Inc. (NASDAQ:RMTI): What Does Its Beta Value Mean For Your Portfolio?
    Simply Wall St.2 days ago

    Rockwell Medical, Inc. (NASDAQ:RMTI): What Does Its Beta Value Mean For Your Portfolio?

    If you're interested in Rockwell Medical, Inc. (NASDAQ:RMTI), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...

  • The Zacks Analyst Blog Highlights: Barclays, Rockwell Medical, NextEra, Belmond and Shaw Communications
    Zacks16 days ago

    The Zacks Analyst Blog Highlights: Barclays, Rockwell Medical, NextEra, Belmond and Shaw Communications

    The Zacks Analyst Blog Highlights: Barclays, Rockwell Medical, NextEra, Belmond and Shaw Communications

  • 7 Hot Momentum Stocks to Watch in 2019
    Zacks19 days ago

    7 Hot Momentum Stocks to Watch in 2019

    These seven hot stocks appear quite promising for momentum-oriented investors, given their solid prospects to outperform the markets this year.

  • GlobeNewswire29 days ago

    Rockwell Medical, Inc. to Present at Biotech Showcase™ 2019

    WIXOM, Mich., Dec. 21, 2018 -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of RMTI earnings conference call or presentation 9-Nov-18 1:30pm GMT

    Q3 2018 Rockwell Medical Inc Earnings Call

  • 5 Beaten-Down Medical Product Stocks to Rebound in 2019
    Zackslast month

    5 Beaten-Down Medical Product Stocks to Rebound in 2019

    As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.

  • GlobeNewswirelast month

    Report: Developing Opportunities within Eaton Vance, IDT, Hemispherx BioPharma, Edgewell Personal Care, Rockwell Medical, and Avadel Pharmaceuticals — Future Expectations, Projections Moving into 2018

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswirelast month

    Rockwell Medical, Inc. Appoints New Vice President, Operations

    Completes Build-Out of Senior Leadership Team by Stuart Paul WIXOM, Mich. , Dec. 10, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company" or "Rockwell Medical") ...

  • PR Newswire2 months ago

    Rockwell Medical, Inc. Appoints New Vice President, Marketing

    WIXOM, Mich., Dec. 3, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (RMTI) (the "Company" or "Rockwell Medical") today announced that Charlie Shiner has been appointed Vice President, Marketing, effective immediately. Mr. Shiner will report to Stuart Paul, President & Chief Executive Officer of the Company. Mr. Shiner joins Rockwell Medical from Otsuka Pharmaceuticals, Ltd., a global pharmaceuticals company focused on the development and marketing of products for the diagnosis and treatment of diseases related to the central nervous system, oncology, gastroenterology, ophthalmology and cardiovascular areas.

  • Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates

    Rockwell Medical (RMTI) delivered earnings and revenue surprises of 33.33% and 11.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Rockwell Medical: 3Q Earnings Snapshot

    The Wixom, Michigan-based company said it had a loss of 10 cents per share. The maker of products used in the treatment of kidney disease and anemia posted revenue of $16.7 million in the period. The company's ...

  • PR Newswire2 months ago

    Rockwell Medical, Inc. Reports Third Quarter 2018 Financial Results

    WIXOM, Mich. , Nov. 9, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company") today reported financial results for the third quarter ended September 30, 2018 , and highlighted ...

  • Analysts Estimate Rockwell Medical (RMTI) to Report a Decline in Earnings: What to Look Out for
    Zacks3 months ago

    Analysts Estimate Rockwell Medical (RMTI) to Report a Decline in Earnings: What to Look Out for

    Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire3 months ago

    Rockwell Medical Appoints New Chief Financial Officer

    WIXOM, Mich. , Nov. 1, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company" or "Rockwell Medical") today announced that Angus Smith has been appointed as Chief Financial ...

  • PR Newswire3 months ago

    Rockwell Medical Schedules Third Quarter 2018 Conference Call

    WIXOM, Mich. , Oct. 29, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ: RMTI) today announced that it will hold a conference call to discuss third quarter 2018 financial results on Friday, November ...

  • PR Newswire3 months ago

    Rockwell Medical Announces Financing Transaction

    WIXOM, Mich., Oct. 15, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (RMTI) (the "Company" or "Rockwell Medical") today announced that it has agreed to sell up to 7,556,675 units to The RBI Opportunities Fund, LLC, an affiliate of Richmond Brothers, Inc. ("Richmond") in a private placement, with each unit consisting of one share of common stock and a warrant to purchase 50% of a share of common stock. The units are being sold at $3.97 per unit, which is equivalent to the closing stock price of the Company's common stock on October 12, 2018, the last trading day prior to pricing this transaction. The warrants, which are not exercisable for six months from closing, have a strike price of $4.96 per full share of common stock and have a five-year term from issuance.

  • PR Newswire3 months ago

    Rockwell Medical Provides Update on IV Triferic

    WIXOM, Mich., Oct. 12, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (RMTI) (the "Company" or "Rockwell Medical") today provided an update on the status of the Company's development of an intravenous ("IV") formulation of the Company's proprietary drug Triferic®, which is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. The Company is in the process of preparing a New Drug Application ("NDA") for IV Triferic and anticipates that it will file the NDA in the fourth quarter of 2018, which would result in a Prescription Drug User Fee Act ("PDUFA") action date in late 2019. "Based on feedback from a pre-NDA meeting with the FDA, we believe that we have an NDA package, including bioequivalence data, that would enable the FDA to review and act on this application before the end of 2019," said Stuart Paul, Rockwell Medical President and Chief Executive Officer.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of RMTI earnings conference call or presentation 14-Aug-18 9:00pm GMT

    Q2 2018 Rockwell Medical Inc Earnings Call

  • PR Newswire4 months ago

    Rockwell Medical Appoints VP, Strategic Accounts

    WIXOM, Mich., Oct. 1, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (RMTI) (the "Company" or "Rockwell Medical") today announced that Anne Boardman has been appointed Vice President, Strategic Accounts, effective today, October 1, 2018. In this newly-established roll, Ms. Boardman will report to Stuart Paul, President & Chief Executive Officer of the Company. Ms. Boardman has substantial experience in renal, biotech and medical sales, sales management and large corporate account management throughout her 30-year career.

  • Business Wire4 months ago

    DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Rockwell Medical, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rockwell Medical, Inc. (“Rockwell Medical” or “the Company”) (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Rockwell Medical had knowledge that the Centers for Medicare and Medicaid Services would not pursue the Company’s plan for reimbursement for Triferic.

  • Business Wire4 months ago

    Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Rockwell Medical, Inc. (RMTI)

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 25, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Rockwell Medical, Inc. (“Rockwell” or the “Company”) (NASDAQ: RMTI) securities between November 8, 2017, and June 26, 2018, inclusive (the “Class Period”). On June 27, 2018, Rockwell disclosed that its auditor resigned, and that the auditor claimed, among other things, that the estimated reserves in Rockwell’s Form 10-Q for the period ended March 31, 2018 were incorrect. The Complaint filed in this class action alleges that the Company made false and misleading statements to the market.

  • ACCESSWIRE4 months ago

    DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Rockwell Medical, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / September 24, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Rockwell Medical, Inc. ("Rockwell Medical" or "the Company") (NASDAQ: RMTI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between March 16, 2018, and June 26, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before September 25, 2018.

  • ACCESSWIRE4 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Rockwell Medical, Inc. of Class Action Lawsuit and Upcoming Deadline - RMTI

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Pomerantz LLP announces that a class actionlawsuit has been filed against Rockwell Medical, Inc. ("Rockwell" or the "Company") (RMTI) and certain of its officers. The class action, filed in United States District Court, Eastern District of New York, and index under 18-cv-04993, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Company securities between November 8, 2017 and June 26, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.